PATRICIA CASTRO to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications PATRICIA CASTRO has written about Xenograft Model Antitumor Assays.
Connection Strength
0.180
-
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer. 2025 Dec; 133(12):1802-1814.
Score: 0.046
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024 10 04; 7(1):1257.
Score: 0.043
-
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade. Cancer Res. 2021 04 01; 81(7):1775-1787.
Score: 0.034
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.031
-
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget. 2017 Jan 24; 8(4):6179-6192.
Score: 0.025